Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 2/20 | 0.33 |
| ▸ | LGMN | Q99538 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20249308 | 0.87 | HRH3 (0.38) | IDH1HRH3TP53DPP4 | |
| SCHEMBL20255275 | 0.84 | DRD3 (0.41) | HRH3 | |
| SCHEMBL20249310 | 0.84 | HRH3 (0.33) | IDH1HRH3DPP4 | |
| SCHEMBL20249368 | 0.81 | HRH3 (0.37) | IDH1HRH3 | |
| SCHEMBL20249339 | 0.78 | HRH3 (0.43) | HRH3TP53 | |
| SCHEMBL20249366 | 0.78 | ALDH1A1 (0.36) | HRH3TP53DPP4 | |
| SCHEMBL20249115 | 0.77 | SLC6A2 (0.42) | HRH3TP53 | |
| SCHEMBL20249300 | 0.76 | PIK3CD (0.43) | IDH1HRH3DPP4 | |
| SCHEMBL20249342 | 0.74 | PARP1 (0.35) | HRH3 | |
| SCHEMBL20249159 | 0.74 | DRD3 (0.33) | TP53DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | IDH1 147/4885LGMN 4798/4885HRH3 2304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.